News articles about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.1608876050294 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Bristol-Myers Squibb Company of a Class Action and a Lead Plaintiff Deadline of April 10, 2018 – BMY (finance.yahoo.com)
- BMY LOSS NOTICE: Rosen Law Firm Reminds Bristol-Myers Squibb Company Investors of Important April 10, 2018 Deadline in Class Action – BMY (finance.yahoo.com)
- A Closer Look at Pfizer’s 4Q17 Growth Drivers (finance.yahoo.com)
- Bristol-Myers Squibb Donates to Make-A-Wish® Mid-Atlantic (patch.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bristol-Myers Squibb Company (BMY) and Lead Plaintiff Deadline: April 10, 2018 (finance.yahoo.com)
Bristol-Myers Squibb (BMY) traded up $0.36 during mid-day trading on Tuesday, reaching $66.43. The company had a trading volume of 6,262,719 shares, compared to its average volume of 7,873,896. The firm has a market capitalization of $108,730.02, a P/E ratio of 112.59, a PEG ratio of 2.05 and a beta of 0.98. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb has a fifty-two week low of $51.56 and a fifty-two week high of $70.05.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.
Several equities research analysts have recently issued reports on BMY shares. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Tuesday, January 16th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $66.81.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb (BMY) Receiving Somewhat Favorable News Coverage, Study Shows” was reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/2018/03/20/bristol-myers-squibb-bmy-receiving-somewhat-positive-news-coverage-accern-reports/2025347.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.